Objective: The purpose of this article was to evaluate the clinical efficacy and safety of a monochromatic 355 nm ultraviolet (UVA) laser in the treatment of vitiligo. Background data: Broadband and narrow-band UV phototherapy has been proposed as an effective therapeutic option in vitiligo patients. Methods: Seventeen consecutive, unselected patients (7 men and 10 women) were enrolled in an open-label, prospective study and treated twice weekly for 8 weeks at a fixed dose of 80–140 J/cm2. Follow-up was 12 weeks. Results: Clinical repigmentation was observed in 15/17 patients (88.23%), with limited side effects (mild post-treatment erythema and itching). Results were maintained during the 12 week phototherapy-free follow-up period. Conclusions: the present report suggests that UVA1 laser could be an applicable therapeutic option in patients with vitiligo.
Get full access to this article
View all access options for this article.
References
1.
TaïebA, PicardoM. Vitiligo. N Engl J Med. 2009; 360:160–169.
2.
RadtkeMA, SchaferI, GajurA, LangenbruchA, AugustinM. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol, 2009; 161:134–139.
3.
MalhotraN, DytocM. The pathogenesis of vitiligo. J Cutan Med Surg, 2013; 17:153–172.
4.
WeichentalM, ShwartzT. Phototherapy: how does UV work?. Photodermatol Photoimmunol Photomed, 2005; 21:260–266.
5.
ChimentoSM, NewlandM, RicottiC, NisticoS, RomanelliP. A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. J Drugs Dermatol, 2008; 7:258–263.
6.
SaracenoR, NisticòS, CapriottiE, ChimentiS. Monochromatic excimer light 308nm in monotherapy and combined to Khellin 4% in the treatment of vitiligo: results of an open study. Dermatol Ther, 2009; 22:391–394.
7.
NisticòS, ChiricozziA, SaracenoR, SchipaniC, ChimentiS. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open controlled randomized study. Photomed Laser Surg, 2012; 30:26–30.
8.
BorderéAC, LambertJ, Van GeelN. Current and emerging therapy for the management of vitiligo. Clin Cosmet Investg Dermatol, 2009; 12:15–25.
9.
ZerbinatiN, PortaleS, CalmieriB, RottigniV, IannittiT. A preliminary study to assess the efficacy of a new UVA1 laser for treatment of psoriasis. Photomed Laser Surg, 2012; 30:610–614.
10.
NisticoS, SaracenoR, ChiricozziA, GiuntaA, Di StefaniA, ZerbinatiN. UVA-1 laser in the treatment of palmoplantar pustular psoriasis. Photomed Laser Surg, 2013; 31:434–438.
11.
BhatnagarA, KanwarAJ, ParsadD, DeD. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol, 2007; 21:638–642.
12.
WesterhofL, NiuweboerL. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol, 2005; 133:1525–1528.
13.
YoungA. The molecular and genetic effects of ultraviolet radiation exposure on skin. In: Photodermatology. HawkJLM (ed.) London: Hodder, Arnold, 1999; pp. 25–42.
14.
GodarDE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol, 1999; 112:3–12.
15.
GuhlS, HartmannK, TapkenhinrichsS, et al.Ultraviolet irradiation induces apoptosis in human immature,but not in skin mast cells. J Invest Dermatol, 2003; 121:837–844.
16.
BreuckmannF, von KobyletzkiG, AvermaeteA, KreuterA, MannherzHG, AltmeyerP. Apoptosis of human dermal endothelial cells as a potential side effect following therapeutic administration of UVA1 irradiation: preliminary results. Arch Dermatol Res, 2002; 294:303–309.
17.
SkovL, HansenH, AllenM, et al.Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor-alpha in human skin. Br J Dermatol, 1998; 138:216–220.
18.
SzegediA, SimicsE, AlekszaM, et al.Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology, 2005; 44:925–931.
19.
McGregorJ, HawkJ. Acute effects of ultraviolet radiation on the skin. In: Fitzpatrick's Dermatology in General Medicine, 5th ed.,Vol. 134. FreedbergI, EisenA, WolfK, et al. (eds.). NewYork: McGraw–Hill, 1999, p. 1555
20.
MutzhasL, HolzleE, HofmanG, PlewigG. A new apparatus with high radiation energy between 320–460 nm: physical description and dermatological applications. J Invest Dermatol, 1981; 76:42–47.
21.
El ZawahriDM, BassiounyDA, SobliRM, et al.Comparative study on efficacy of UVA1 vs. narrow-band UVB phototherapy in the treatment of vitiligo. Photodermatol Photoimmunol Photomed, 2012; 28:84–90.
Van der MolenRG, Out-LuitingC, ClaasFH, et al.Ultraviolet-B radiation induces modulation of antigen presentation of herpes simplex virus by human epidermal cells. Hum Immunol, 2001; 62:589–597.
24.
SacherC, KonigC, Scharffetter–KochanekK, et al.Bullous pemphigoid in a patient treated with UVA-1 phototherapy for disseminated morphea. Dermatology, 2001; 202:54–57.
25.
WallenfangK, StadlerR. Association between UVA1 and PUVA bath therapy and development of malignant melanoma. Hautarzt, 2001; 52:705–707.
26.
AutierP, DoreJF, EggermontAM, CoeberghJW. Epidemiological evidence that UVA radiation is involved in the genesis of cutaneous melanoma. Curr Opin Oncol, 2011; 23:189–186.
27.
CoelhoSG, HearingVJ. UVA tanning is involved in the increased incidence of skin cancers in fair-skinned young women. Pigment Cell Melanoma Res, 2010; 23:57–63.
28.
RidleyAJ, WhitesideJR, McMillanTJ, AllinsonSL. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int J Radiat Biol, 2009; 85:177–185.
29.
BesaratiniaA, SynoldTW, ChenHH, et al.DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc Natl Acad Sci USA, 2005; 102:10,058–10,063.
30.
SchnoppC, RadR, WeidingerA, et al.Fox-P3-positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium-dose UVA1 therapy. Photodermatol Photoimmunol Photomed, 2007; 23:81–85.
